NCT02611167 is a Phase 1 clinical trial of Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg) in Parkinson's Disease, sponsored by The University of Texas Health Science Center, Houston.

Who is sponsoring NCT02611167?

NCT02611167 is sponsored by The University of Texas Health Science Center, Houston.

What drugs are being tested in NCT02611167?

Interventions in NCT02611167: Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg), Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg), Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg), Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg).

What condition does NCT02611167 study?

NCT02611167 studies Parkinson's Disease.

Is NCT02611167 still recruiting?

NCT02611167 is currently completed. Last updated 29 November 2023.

Last reviewed 2023-11-29 · How we verify

NCT02611167

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease

Completed Phase 1 Last updated 29 November 2023

What this trial tests

Phase 1 trial testing Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg) in Parkinson's Disease in 20 participants. Completed in 18 September 2019.

Timeline

1 November 2017

Primary endpoint
18 September 2019

18 September 2019

Quick facts

Lead sponsor	The University of Texas Health Science Center, Houston
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 November 2017
Primary completion	18 September 2019
Estimated completion	18 September 2019
Sites	1 location across United States

Drugs / interventions tested

Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg) — full drug profile →
Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg) — full drug profile →
Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg) — full drug profile →
Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg) — full drug profile →

Conditions studied

Parkinson's Disease — all drugs for Parkinson's Disease →

Sponsor

The University of Texas Health Science Center, Houston

Who can join

Adults 45 to 70, any sex, with Parkinson's Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the safety, feasibility, and efficacy of intravenous allogeneic bone marrow-derived mesenchymal stem cell (MSC) therapy for idiopathic Parkinson's disease (iPD).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

A Brief Overview of Global Trends in MSC-Based Cell Therapy.
Jovic D, Yu Y, Wang D, Wang K, et al · · 2022 · cited 186× · PMID 35344199 · DOI 10.1007/s12015-022-10369-1
Clinical Trials Based on Mesenchymal Stromal Cells are Exponentially Increasing: Where are We in Recent Years?
Galderisi U, Peluso G, Di Bernardo G. · · 2022 · cited 175× · PMID 34398443 · DOI 10.1007/s12015-021-10231-w
An Update on the Progress of Isolation, Culture, Storage, and Clinical Application of Human Bone Marrow Mesenchymal Stem/Stromal Cells.
Chu DT, Phuong TNT, Tien NLB, Tran DK, et al · · 2020 · cited 168× · PMID 31973182 · DOI 10.3390/ijms21030708
Differentiation of Human Mesenchymal Stem Cells towards Neuronal Lineage: Clinical Trials in Nervous System Disorders.
Hernández R, Jiménez-Luna C, Perales-Adán J, Perazzoli G, et al · · 2020 · cited 95× · PMID 31649208 · DOI 10.4062/biomolther.2019.065
The potential use of mesenchymal stem cells and their exosomes in Parkinson's disease treatment.
Heris RM, Shirvaliloo M, Abbaspour-Aghdam S, Hazrati A, et al · · 2022 · cited 75× · PMID 35902981 · DOI 10.1186/s13287-022-03050-4
MSCs vs. iPSCs: Potential in therapeutic applications.
Thanaskody K, Jusop AS, Tye GJ, Wan Kamarul Zaman WS, et al · · 2022 · cited 59× · PMID 36407112 · DOI 10.3389/fcell.2022.1005926
Challenges and translational considerations of mesenchymal stem/stromal cell therapy for Parkinson's disease.
Fričová D, Korchak JA, Zubair AC. · · 2020 · cited 55× · PMID 33298940 · DOI 10.1038/s41536-020-00106-y
Stem Cell-Based Therapies for Parkinson Disease.
Liu Z, Cheung HH. · · 2020 · cited 55× · PMID 33137927 · DOI 10.3390/ijms21218060

Verify or expand the search:

Other recruiting trials for Parkinson's Disease

Currently open trials in the same condition.

NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07330258 — A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite · recruiting
NCT07384429 — Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease · Phase 4 · recruiting
NCT07384442 — Effects of Targeted Temporal Interference Stimulation of Cerebellar Nuclei on Tremor and Gait Disturbance in Parkinson's · NA · recruiting
NCT06562569 — Non-invasive VNS for PD Gait · NA · recruiting

Other The University of Texas Health Science Center, Houston trials

Trials by the same sponsor.

NCT04200729 — Povidone-iodine Irrigation for Prevention of Intra-abdominal Abscess in Pediatric Perforated Appendicitis: a Multi-cente · Phase 4 · not yet recruiting
NCT07225062 — Improving HIV Prevention and Substance Use Post-Sexual Assault Services · NA · not yet recruiting
NCT07396974 — Increasing Treatment Access in Trauma Exposed Children: Developing an Adapted Step One Intervention (RCT) · NA · not yet recruiting
NCT07170163 — Navigating the Transition to Adulthood: A Dual Language Mobile App for Latino Youth With ASD and Their Families · NA · not yet recruiting
NCT06915441 — Lipid Infusions to Optimize Nutrition Trial · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02611167 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Texas Health Science Center, Houston
Last refreshed: 29 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02611167.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing